Old gastrointestinal drug slows aging, McGill researchers say

January 07, 2009

Recent animal studies have shown that clioquinol - an 80-year old drug once used to treat diarrhea and other gastrointestinal disorders - can reverse the progression of Alzheimer's, Parkinson's and Huntington's diseases. Scientists, however, had a variety of theories to attempt to explain how a single compound could have such similar effects on three unrelated neurodegenerative disorders.

Researchers at McGill University have discovered a dramatic possible new answer: According to Dr. Siegfried Hekimi and colleagues at McGill's Department of Biology, clioquinol acts directly on a protein called CLK-1, often informally called "clock-1," and might slow down the aging process. The advance online edition of their study was published in Oct. 2008 in the Journal of Biological Chemistry.

"Clioquinol is a very powerful inhibitor of clock-1," explained Hekimi, McGill's Strathcona Chair of Zoology and Robert Archibald & Catherine Louise Campbell Chair in Developmental Biology. "Because clock-1 affects longevity in invertebrates and mice, and because we're talking about three age-dependent neurodegenerative diseases, we hypothesize that clioquinol affects them by slowing down the rate of aging."

Once commonly prescribed in Europe and Asia for gastrointestinal problems like diarrhea and shigella, clioquinol was withdrawn from the market after being blamed for a devastating outbreak of subacute myelo-optic neuropathy (SMON) in Japan in the 1960s. However, because no rigorous scientific study was conducted at the time, and because clioquinol was used safely by millions before and after the Japanese outbreak, some researchers think its connection to SMON has yet to be proven.

The exact mechanism of how clioquinol inhibits CLK-1 is still under investigation, Hekimi said. "One possibility is that metals are involved as clioquinol is a metal chelator," he explained. Chelation is a type of binding to metal ions and is often used to treat heavy metal poisoning.

Hekimi is optimistic but cautious when asked whether clioquinol could eventually become an anti-aging treatment.

"The drug affects a gene which when inhibited can slow down aging," he said. "The implication is that we can change the rate of aging. This might be why clioquinol is able to work on this diversity of diseases that are all age-dependent."

However, he admits to being concerned about how people may interpret his results.

"The danger is that you can buy a kilogram of this compound at a chemical wholesaler, but we don't want people to start experimenting on themselves. Clioquinol can be a very toxic substance if abused, and far more research is required."

McGill University

Clioquinol
by Ronald Cohn Jesse Russell (Author)

High Quality Content by WIKIPEDIA articles! Clioquinol (Iodochlorhydroxyquin) is an antifungal drug and antiprotozoal drug. It is neurotoxic in large doses. It is a member of a family of drugs called hydroxyquinolines which inhibit certain enzymes related to DNA replication. The drugs have been found to have activity against both viral and protozoal infections. This book was created using print-on-demand technology.

Alzheimer's study will target plaque formation.(Rx): An article from: Internal Medicine News
by Heidi Splete (Author)

This digital document is an article from Internal Medicine News, published by International Medical News Group on May 1, 2005. The length of the article is 723 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Alzheimer's study will target plaque formation.(Rx)
Author: Heidi Splete
Publication: Internal Medicine News (Magazine/Journal)
Date: May 1, 2005
Publisher: International Medical News Group
Volume: 38 Issue: 9 Page: 48(1)

Distributed by Thomson...

Clioquinol: Availability and instructions for use : report of an international survey carried out for the International Organization of Consumers' Unions by the Research Institute for Consumer Affairs
by Michael Dunne (Author)

Novel drug targets plaque formation in Alzheimer's study.(Geriatric Medicine): An article from: Family Practice News
by Heidi Splete (Author)

This digital document is an article from Family Practice News, published by International Medical News Group on May 15, 2005. The length of the article is 616 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Novel drug targets plaque formation in Alzheimer's study.(Geriatric Medicine)
Author: Heidi Splete
Publication: Family Practice News (Magazine/Journal)
Date: May 15, 2005
Publisher: International Medical News Group
Volume: 35 Issue: 10 Page: 52(1)

Distributed by Thomson...

Inventing the AIDS Virus
by Peter H. Duesberg (Author)

An eminent scientist and pioneer in the discovery of retroviruses challenges the widely accepted belief that HIV is the cause of AIDS. Duesberg argues that HIV is merely a harmless passenger virus that does not cause AIDS. Sure to spark intense debate, this provocative book offers an original and incisive critique of the rise and fall of HIV.

Neurobehavioral Toxicology: Neurological and Neuropsychological Perspectives, Volume III: Central Nervous System (Studies on Neuropsychology, Neurology and Cognition)
by Stanley Berent (Author), James W. Albers (Author)

This is the final volume in a three-volume work that has addressed the scientific methodologies relevant to clinical neurobehavioral toxicology. Volume I focused on basic concepts and methodologies in Neurobehavioral Toxicology, with Volume II focusing on the peripheral nervous system. Volume III attends to what is known about industrial and environmental chemicals, medicines, and substances of abuse and how these agents affect the central nervous system. All substances have the capacity to be toxic, depending on factors that include the physical properties of the chemical or compound, organism related variables, or interaction between the two. These substances on the other hand and as a result of these same factors might be used therapeutically or even recreationally. The difference...

Management of Positive Patch Test Reactions
by Jan E. Wahlberg (Editor), Peter Elsner (Editor), Lasse Kanerva (Editor), Howard I. Maibach (Editor)

Commercially available chemicals used for patch testing are the main focus of this book. It is the first book which provides a short and concise explanation to physicians, patients, and employees on how to minimize allergic contact dermatitis when patch testing is completed. The second book of this mini-series, "Patch testing and Prick testing" covers the new standard of patch testing and prick testing procedures in an efficient and practical way. Both of these well-structured books should not be missed by any physician in daily practise when treating patients with dermatological problems.

Bad Medicine: The Prescription Drug Industry in the Third World
by Milton Silverman (Author), Mia Lydecker (Author), Philip Lee M.D (Author)

The pharmaceutical industry has long and vehemently insisted that it has the willingness, the dedication, and the ability to police itself to insure that the public will not be unnecessarily harmed or defrauded. As the record shows with painful clarity, however, virtually no industry or professional group has ever adequately policed itself, and the pharmaceutical industry is no exception. Where the most flagrant abuses have been exposed and corrected, major credit must probably be divided among the media that publicized the situation, consumer groups that applied pressure, government officials who took actions that were often unpopular, and individual members of the pharmaceutical industry who had the courage to face up to their social responsibilities.

In this book, the authors...

Pharmaco-Vigilance from A to Z: Adverse Drug Event Surveillance
by Barton L. Cobert MD (Author), Pierre Biron MD (Author)

Pharmacovigilance from A to Z is an authoritative text focusing on the common questions and procedures involved in prescribed-drug monitoring. The alphabetized format provides an easy-to-use reference, while a separate section of the book guides the reader logically from topic to topic to form related "chapters."

Pocket Guide to Eczema and Contact Dermatitis
by Colin Holden (Author), Lucy Ostlere (Author)

The eczemas account for roughly 10% of hospital referrals of skin conditions. The diseases affect all age groups and are increasing in incidence.
They have a profound effect on quality of life and are a common cause of occupational disease.
Increasingly management of eczema will be provided within the community, perhaps within dedicated nurse-led disease clinics.
There are many types of eczema, and correct diagnosis is crucial to identify curable variants, to avoid mismanagement and enable appropriate referral to hospital.
This illustrated short textbook will aid GPs and dermatology nurses in hospital and the community to recognise eczema subtypes, institute appropriate management, and pick out possible cases of contact allergy which will allow appropriate referral for...